Abstract:Background CD4+CD25+Foxp3+ T regulatory (Treg) cells play a key role in peripheral tolerance. Rapamycin was approved by the FDA to preserve renal allografts and to be efficacious in patients with several autoimmune diseases [1]. Objectives To investigate the status of Treg cells in active refractory rheumatoid arthritis (RA) and the effects of rapamycin on patients with RA. Methods Forty-five active refractory RA patients were enrolled. Rapamycin was used at a dose of 0.5 mg every 2 days [the preliminary, open-label clinical trial of rapamycin (Clinical Trials.gov number: ChiCTR-IPR-17010307)]. Clinical improvement and immunological assessments were performed before 1st rapamycin dose and 12 weeks post treatment. Blood samples were obtained from RA patients and 75 healthy volunteers for estimation of CD4+ T cell subsets. Results Two patients dropped out due to non-compliance. As compared to healthy controls (median of Treg cells: 33.32 cell/ul), the absolute counts of circulating Treg cells were significantly decreased in patients with active refractory RA (median: 27.17 cell/ul; P=0.046). While the median ratios of Th17/Treg cells in patients with active refractory RA (median: 0.26) were significantly higher than those of healthy volunteers (median: 0.19; P=0.029). No difference in the absolute counts of circulating Th17 cells and Th1 cells was observed between patients with active refractory RA and healthy subjects. Rapamycin treatment led to clinical improvement with the median post-treatment DAS28-ESR decreasing when compared to baseline (from 4.19 to 3.78) in active refractory RA patients. Sixteen patients (16/43 patients, 37.21%) achieved an EULAR moderate response and 6 patients (6/43 patients, 13.95%) reached good response at week 12. Rapamycin administration resulted in an increase in the absolute counts of Treg cells in active refractory RA patients, from a median of 27.17 cell/ul (at week 0) to 37.57 cell/ul (at week 12) (P=0.041). The ratios of Th17/Treg cells shows a reduction from a median of 0.26 at baseline to 0.20 at week 12, but the difference is not significant (P =0.376). No significant difference was observed in the absolute counts of circulating Th17 and Th1 cells after rapamycin treatment. Interestingly, we observed that Treg cells increased before the complete remission of the disease (DAS28 score <2.6) in patients with active refractory RA. At week 12, the mean dose of prednisone which refractory RA patients were receiving decreased from 11.98 mg/d to 8.31 mg/d, with a dose reduced by ≥30% than that at baseline. The categories of DMARDs use were also reduced (P<0.05). No serious adverse events was observed during the 12-week period of rapamycin treatment. Conclusions Reduced absolute number of Treg cells was found in the patients with active refractory RA, indicating an imbalance between Th17 and Treg cells. Rapamycin elicits rapid improvement of disease activity via restoring circulating Treg cells numbers in patients with active refractory RA. References Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016. 12(3): 169–82. Disclosure of Interest None declared

The Influence of Rapamycin on BTLA Expression of Human Peripheral Blood T Lymphocytes

Combination of Rapamycin and Il-2 Do Not Affect Antigen Presentation Ability of Rat B Cell and Could Promote Tregs Proliferation and Inhibitory Activity

The Immunosuppressive Effect of Rapamycin on Lymphocytic Proliferation and DTH、GVHR

Rapamycin in Combination with Donor-Specific CD4+CD25+Treg Cells Amplified in Vitro Might Be Realize the Immune Tolerance in Clinical Organ Transplantation

The Effects of Rapamycin on Regulatory T Cells: Its Potential Time-Dependent Role in Inducing Transplant Tolerance.

[Effect of Rapamycin on CD4(+) CD25(+) Regulatory T Cells in Allo-Transplantation Tolerance Model].

Effects of Rapamycin on Proliferation, Function and Cell-Cycle of Mouse T Lymphocytes in Vitro

Effects of rapamycin on number and activity of endothelial progenitor cells

THU0176 Efficiency and safety of rapamycin combined with low-dose IL-2 treatment compared with methotrexate in patients with rheumatoid arthritis

The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.

AB0382 Rapamycin Selectively Increases Circulating Tregcellsand Maintain Remission of Patients with Rheumatoid Arthritis

[Effects of Rapamycin on angiogenesis and tumor progression in human hepatocellular carcinoma implantation mice].

AB0421 Rapamycin Reduces Disease Activity Through Restoring Regulatory T Cell Numbers in Patients with Active Refractory Rheumatoid Arthritis

Rapamycin Inhibiting Jurkat T Cells Viability Through Changing Mrna Expression of Serine/Threonine Protein Phosphatase 2A

Deep phenotyping of T cell populations under long-term treatment of tacrolimus and rapamycin in patients receiving renal transplantations by mass cytometry

Immunomodulation of T Cell-Mediated Alloimmunity by Proximity to Endothelial Cells under the Mammalian Target of Rapamycin Blockade.

Effects of Rapamycin on the Differentiation and Function of Macrophages in Vitro

[Preventive and Therapeutic Effects of Rapamycin Against Autoimmune Hepatitis and Liver Fibrosis and Possible Mechanisms].

[Inhibition of Growth and Metastasis of Hepatocellular Carcinoma by Rapamycin: Experiment with Mice].

Limited Efficacy of Rapamycin Monotherapy in Vascularized Composite Allotransplantation.

Effect of New Immunosuppressant-Rapamycin on One-way Mixed Lymphocyte Culture